Fabupharm expands product range
Local pharmaceutical company Fabupharm is keen to roll out new products.
Bolstered by equity partner EOS Capital, Fabupharm is shifting some of its attention towards the production of additional tablets and capsules.
This was revealed to Namibian Sun by one of the pharmaceutical company''s senior managers, Fanie Badenhorst.
The new product range will include cardiovascular, anti-diabetic, antimalarial and anti-inflammatory products.
Fabupharm has already started work on the expansion of its facility and the registration of the envisaged new products, hoping to be ready by the government''s next tender period in December 2017.
Said Badenhorst: “We are going to focus on the manufacture of different dosage forms such as capsules, tablets and sachets.”
He explained that the process would require significant additional capital, financed by selling 35% stake to equity partner EOS Capital.
“When our new production facility is finalised our production capacity will be 50 000 capsules and 180 000 tablets per hour.”
He said Fabupharm has until December 2017 to make sure its new solid dosage forms are registered with the Namibian Medicines Regulatory Council.
Asked whether Fabupharm would supply the additional products to the Ministry of Health, Badenhorst responded cautiously: “There are not exactly any guarantees but we also focus on the private and export markets.”
Giving an update on Fabupharm''s planned manufacturing of antiretroviral drugs, he added: “It was put on hold following government''s decision to set up a facility of their own. We did not go through with it, pending the final decision by the government.
“The physical planning of such a facility and sourcing of equipment has already been done. Some of our new equipment can be utilised for the production of ARV products but must be in a separate facility. The government''s project team did meet with us, but we are not sure about their intentions to manufacture antiretroviral drugs.”
OGONE TLHAGE
This was revealed to Namibian Sun by one of the pharmaceutical company''s senior managers, Fanie Badenhorst.
The new product range will include cardiovascular, anti-diabetic, antimalarial and anti-inflammatory products.
Fabupharm has already started work on the expansion of its facility and the registration of the envisaged new products, hoping to be ready by the government''s next tender period in December 2017.
Said Badenhorst: “We are going to focus on the manufacture of different dosage forms such as capsules, tablets and sachets.”
He explained that the process would require significant additional capital, financed by selling 35% stake to equity partner EOS Capital.
“When our new production facility is finalised our production capacity will be 50 000 capsules and 180 000 tablets per hour.”
He said Fabupharm has until December 2017 to make sure its new solid dosage forms are registered with the Namibian Medicines Regulatory Council.
Asked whether Fabupharm would supply the additional products to the Ministry of Health, Badenhorst responded cautiously: “There are not exactly any guarantees but we also focus on the private and export markets.”
Giving an update on Fabupharm''s planned manufacturing of antiretroviral drugs, he added: “It was put on hold following government''s decision to set up a facility of their own. We did not go through with it, pending the final decision by the government.
“The physical planning of such a facility and sourcing of equipment has already been done. Some of our new equipment can be utilised for the production of ARV products but must be in a separate facility. The government''s project team did meet with us, but we are not sure about their intentions to manufacture antiretroviral drugs.”
OGONE TLHAGE
Comments
Namibian Sun
No comments have been left on this article